top of page

PHERGAIN

CHEMOTHERAPY-FREE TRASTUZUMAB AND PERTUZUMAB IN HER2-POSITIVE (HUMAN EPIDERMAL RECEPTOR) BREAST CANCER: FDG-PET RESPONSE-ADAPTED STRATEGY. THE PHERGAIN STUDY

CLINICAL TRIAL DETAILS

THE STUDY ASSESS THE EARLY METABOLIC EFFECTS OF NEOADJUVANT TREATMENT WITH TRASTUZUMAB AND PERTUZUMAB (± ENDOCRINE THERAPY) ON THE PRIMARY TUMOR AND AXILLARY LYMPH NODES AND THEIR PREDICTIVE VALUE FOR PATHOLOGIC COMPLETE RESPONSE (PCR) IN THE BREAST AND AXILLA.

AND ALSO ASSESS 3-YEAR INVASIVE DISEASE-FREE SURVIVAL (IDFS) IN PATIENTS WITH HER2-POSITIVE (HER: HUMAN EPIDERMAL RECEPTOR) BREAST CANCER TREATED WITH NEOADJUVANT TRASTUZUMAB AND PERTUZUMAB (± ENDOCRINE THERAPY) USING A FDG-PET RESPONSE-ADAPTED STRATEGY.

COUNTRY

STATUS

TUMOR TYPE

PHASE

N

SITES

HER2+ EBC

56

377

II

Spain, Portugal, France, UK, Italy, Belgium, Germany

Analysis

PRESS RELEASE

home_fondo_you_barra.jpg

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

TRIAL SITES

home_fondo_you_barra.jpg
Hospital Universitari Vall D'Hebron (Spain) Institut Català d' Oncologia L'Hospitalet (ICO) (Spain) Hospital Clínic i Provincial de Barcelona (Spain) Institut Català d' Oncologia Badalona (ICO) (Spain) Hospital Universitario La Paz (Spain) Hospital Universitario Virgen del Rocío (Spain) Hospital Universitario Reina Sofía (Spain) Hospital Universitario Virgen de la Victoria (Spain) Complejo Hospitalario de Jaén (Spain) Hospital Clínico Universitario de Valencia (Spain) Consorci Hospital General Universitari de València (Spain) Hospital Universitari i Politècnic La Fe (Spain) Instituto Valenciano de Oncología (IVO) (Spain) Hospital Provincial de Castellón (Spain) Complejo Hospitalario Universitario A Coruña (CHUAC) (Spain) Complejo Hospitalario Universitario de Santiago (CHUS) (Spain) Hospital Universitario de Burgos (Spain) Hospital Universitario Miguel Servet (Spain) Hospital Arnau de Vilanova de Valencia (Spain) Hospital Universitario Ramón y Cajal (Spain) Institut Català d' Oncologia Girona (ICO) (Spain) Hospital Universitari Sant Joan de Reus (Spain) Hospital Universitario Arnau de Vilanova de Lleida (Spain) Hospital Universitario Dr. Peset (Spain) Hospital Clínico Universitario Lozano Blesa (Spain) Hôpital Tenon AP-HP (France) Hopital Europeen Georges Pompidou (France) Institut Universitaire du Cancer Toulouse, Toulouse (France) Centre Paul Strauss (France) Groupe Hospitalier Diaconesses (France) CLCC d'Auvergne. Centre Jean Perrin. Clermont Ferrand (France) Institute de Cancerologie de Lorraine, Nancy (France) Ospedale Antonio Perrino (Italy) Ospedale San Gerardo (Italy) Instituto Europeo di Oncologia (Italy) Istituti Ospitalieri Cremona (Italy) Ospedale Guglielmo da Saliceto (Italy) Ospedale S.Orsola Bologna (Italy) Ospedale Mantova (Italy) Barts Cancer Institute (UK) The Christie NHS Foundation Trust (UK) Royal Cornwall Hospital NHS Trust (UK) National Center for Tumor Disease (NCT) (Germany) Hämatologisch-Onkologische Schwerpunktpraxis (Germany) Kliniken Essen Mitte (Germany) Klinikum Rechts der Isar (Germany) Klinikum der Med. Fakultät Halle (Germany) Städtisches Klinikum „St. Georg“ Leipzig (Germany) Institut Jules Bordet (Belgium) Hospital Da Luz Lisboa (Portugal) Breast Cancer Unit of Centro Hospitalar São João (Portugal) Hospital Senhora da Oliveira Guimarães (Portugal) Hospital Fernando da Fonseca (Portugal) Centro Hospitalar de Trás-os-Montes e Alto Douro (Portugal) Hospital Beatriz Ângelo (Portugal) Hospital do Santo Antonio (Portugal)
bottom of page